The estimated Net Worth of Mark Pomeranz is at least $1.1 Million dollars as of 19 November 2021. Mr. Pomeranz owns over 4,000 units of Motus GI Inc stock worth over $5,111 and over the last 7 years he sold MOTS stock worth over $0. In addition, he makes $1,091,150 as President, Chief Operating Officer, and Director at Motus GI Inc.
Mark has made over 6 trades of the Motus GI Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of MOTS stock worth $2,040 on 19 November 2021.
The largest trade he's ever made was buying 65,000 units of Motus GI Inc stock on 17 February 2021 worth over $2,015. On average, Mark trades about 7,409 units every 125 days since 2018. As of 19 November 2021 he still owns at least 164,857 units of Motus GI Inc stock.
You can see the complete history of Mr. Pomeranz stock trades at the bottom of the page.
Mark L. Pomeranz serves as President, Chief Operating Officer, Director of the Company. Mr. Pomeranz has served as Chief Operating Officer since September 24, 2018. Prior to his tenure as our Chief Operating Officer, Mr. Pomeranz served as our Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform in the EU. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. Mr. Pomeranz was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd. and his business and leadership experience in the medical technology sector; his broad scientific background is also seen as an asset to us.
As the President, Chief Operating Officer, and Director of Motus GI Inc, the total compensation of Mark Pomeranz at Motus GI Inc is $1,091,150. There are 2 executives at Motus GI Inc getting paid more, with Timothy Moran having the highest compensation of $1,659,360.
Mark Pomeranz is 58, he's been the President, Chief Operating Officer, and Director of Motus GI Inc since 2018. There are 2 older and 7 younger executives at Motus GI Inc. The oldest executive at Motus GI Holdings Inc is Samuel Nussbaum, 71, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE, FL, 33301.
Over the last 7 years, insiders at Motus GI Inc have traded over $2,638,819 worth of Motus GI Inc stock and bought 3,952,265 units worth $13,986,863 . The most active insiders traders include Advisors Llcperceptive Life..., Larry Noracle Partners Lp F..., and David P Hochman. On average, Motus GI Inc executives and independent directors trade stock every 33 days with the average trade being worth of $4,105. The most recent stock trade was executed by Andrew Lawrence Taylor on 19 November 2021, trading 2,000 units of MOTS stock currently worth $1,020.
motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.
Motus GI Inc executives and other stock owners filed with the SEC include: